Previous 10 | Next 10 |
5 Penny Stocks To Watch Tomorrow It’s never a guarantee that penny stocks will always return thousands of percentage points. It’s also not a complete lock that all penny stocks will end in losses. What’s the difference between winning traders and losing trad...
VYNE Therapeutics ([[VYNE]] +4.3%) has announced a coverage update for its ZILXI topical foam, 1.5%, FDA approved minocycline product for use in rosacea for the treatment of inflammatory lesions in adults.Express Scripts has elected to cover ZILXI effective October 2, on Express Scripts'...
VYNE Therapeutics Announces Covered Status for ZILXI™ (minocycline) with Express Scripts Coverage Effective October 2, 2020 on Express Scripts National Preferred, Flex, and Basic Formularies PR Newswire BRIDGEWATER, N.J., Oct. 7, 2020 BRIDGEWATER, N.J. ...
VYNE Therapeutics (VYNE) is up 10% after H.C. Wainwright reiterated its Buy rating and boosted its price target on ZILXI's (minocycline) entry to U.S. pharmaceutical market.The firm raised its price target to $3.50 from $3, implying an approximately 17% upside. Analyst Oren Liv...
VYNE Therapeutics (VYNE) announces that its novel ZILXI (minocycline) topical foam, 1.5% is now available by prescription for the treatment of inflammatory lesions of rosacea in adults.This new once-daily therapy will be available in retail, community and specialty pharmacies nationwide. The ...
VYNE Therapeutics Announces ZILXI™ (minocycline) topical foam, 1.5% Available in Pharmacies Nationwide on October 1st ZILXI is the First FDA Approved Minocycline Product for the Treatment of Inflammatory Lesions of Rosacea in Adults ZILXI Offers Efficacy with Low Syst...
ZILXI is the First FDA Approved Minocycline Product for the Treatment of Inflammatory Lesions of Rosacea in Adults ZILXI Offers Efficacy with Low Systemic Absorption BRIDGEWATER, N.J., Oct. 01, 2020 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq...
Since the time of my last article, Vyne's market cap has dropped from $330 million to just $285 million. Despite a slowdown in the Amzeeq launch due to the pandemic, sales seem to be picking back up and the long-term trajectory remains strong. Vyne looks substantially undervalued ...
BRIDGEWATER, N.J., Sept. 23, 2020 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that the Company will host a physician symposium on AMZEEQ ® and ZILXI™ on Thursday, October 1, 2020 from 12pm ...
The following slide deck was published by VYNE Therapeutics Inc. in conjunction with this Read more ...
News, Short Squeeze, Breakout and More Instantly...
VYNE Therapeutics Inc Com Company Name:
VYNE Stock Symbol:
NASDAQ Market:
VYNE Therapeutics Inc Com Website:
BRIDGEWATER, N.J., July 16, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory con...
BRIDGEWATER, N.J., July 09, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory con...
BRIDGEWATER, N.J., June 26, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory co...